Gemcitabine Maintenance in Lung Cancer Could Be Low Cost Alternative

This video highlights a study that tested an alternative maintenance strategy determined by response to induction chemotherapy for patients with advanced non-squamous non–small-cell lung cancer.

In this video, Maurice Pérol, MD, of the Cancer Research Center of Lyon in France, discusses a study that tested an alternative maintenance strategy for advanced non-squamous non–small-cell lung cancer (NSCLC), determined by a patient’s response to induction chemotherapy.

Patients in the study were randomized 1:1 to either cisplatin/gemcitabine induction followed by gemcitabine maintenance in those with an objective response and then second-line pemetrexed, or switch maintenance with pemetrexed for those with stable disease; vs standard cisplatin/pemetrexed induction followed by maintenance pemetrexed.

Pérol presented the results of the study (abstract 9003) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago..